Article information
-
AUTHOR CONTRIBUTIONS: Conception and design: W.Y.L., H.K. Development of methodology: H.K., J.J., K.D.H., Y.G.P. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.J., K.D.H., Y.G.P. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.J., K.D.H., Y.G.P. Writing, review, and/or revision of the manuscript: H.K., J.H.C., D.Y.L., J.M.H. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K.D.H., H.K. Study supervision: S.E.P., E.J.R., W.Y.L.
-
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
Fig. 1Annual incidence of thyroid nodules in 2006 to 2015.
Fig. 2Annual incidence of hypothyroidism in patients taking thyroid hormone in 2006 to 2015.
Fig. 3Annual incidence of hyperthyroidism in patients undergoing treatment in 2006 to 2015.
Fig. 4Changes in the prescription patterns of antithyroid drug in patients with hyperthyroidism. CAMZ, carbimazole; MMI, methimazole; PTU, propylthiouracil.
Table 1Prevalence of Thyroid Nodules in 2015
|
Total |
Men |
Women |
Population |
Events |
Prevalencea |
Population |
Events |
Prevalencea |
Population |
Events |
Prevalencea |
Total |
51,834,660 |
820,283 |
15.82 |
25,933,249 |
154,032 |
5.94 |
25,901,411 |
666,251 |
25.72 |
Age group, yr |
|
|
|
|
|
|
|
|
|
≤9 |
4,619,384 |
2,237 |
0.48 |
2,375,043 |
607 |
0.26 |
2,244,341 |
1,630 |
0.73 |
10–19 |
5,709,599 |
10,049 |
1.76 |
2,977,410 |
2,665 |
0.90 |
2,732,189 |
7,384 |
2.70 |
20–29 |
6,881,546 |
31,148 |
4.53 |
3,643,304 |
4,970 |
1.36 |
3,238,242 |
26,178 |
8.08 |
30–39 |
7,824,337 |
91,382 |
11.68 |
4,019,283 |
14,997 |
3.73 |
3,805,054 |
76,385 |
20.07 |
40–49 |
8,871,241 |
169,997 |
19.16 |
4,502,350 |
27,918 |
6.20 |
4,368,891 |
142,079 |
32.52 |
50–59 |
8,332,932 |
248,945 |
29.87 |
4,184,758 |
43,247 |
10.33 |
4,148,174 |
205,698 |
49.59 |
60–69 |
5,064,740 |
173,674 |
34.29 |
2,457,128 |
36,997 |
15.06 |
2,607,612 |
136,677 |
52.41 |
70–79 |
3,153,746 |
76,976 |
24.41 |
1,352,287 |
18,560 |
13.72 |
1,801,459 |
58,416 |
32.43 |
≥80 |
1,377,135 |
15,875 |
11.53 |
421,686 |
4,071 |
9.65 |
955,449 |
11,804 |
12.35 |
Table 2Prevalence of Hypothyroidism in Patients Taking Thyroid Hormone in 2015
|
Total |
Men |
Women |
Population |
Events |
Prevalencea
|
Population |
Events |
Prevalencea
|
Population |
Events |
Prevalencea
|
Total |
51,834,660 |
826,258 |
15.94 |
25,933,249 |
133,515 |
5.15 |
25,901,411 |
692,743 |
26.75 |
Age group, yr |
|
|
|
|
|
|
|
|
|
≤9 |
4,619,384 |
5,371 |
1.16 |
2,375,043 |
2,657 |
1.12 |
2,244,341 |
2,714 |
1.21 |
10–19 |
5,709,599 |
6,504 |
1.14 |
2,977,410 |
1,822 |
0.61 |
2,732,189 |
4,682 |
1.71 |
20–29 |
6,881,546 |
20,853 |
3.03 |
3,643,304 |
3,149 |
0.86 |
3,238,242 |
17,704 |
5.47 |
30–39 |
7,824,337 |
96,121 |
12.28 |
4,019,283 |
12,058 |
3.00 |
3,805,054 |
84,063 |
22.09 |
40–49 |
8,871,241 |
164,334 |
18.52 |
4,502,350 |
25,809 |
5.73 |
4,368,891 |
138,525 |
31.71 |
50–59 |
8,332,932 |
234,732 |
28.17 |
4,184,758 |
34,698 |
8.29 |
4,148,174 |
200,034 |
48.22 |
60–69 |
5,064,740 |
174,322 |
34.42 |
2,457,128 |
28,939 |
11.78 |
2,607,612 |
145,383 |
55.75 |
70–79 |
3,153,746 |
96,687 |
30.66 |
1,352,287 |
18,802 |
13.90 |
1,801,459 |
77,885 |
43.23 |
≥80 |
1,377,135 |
27,334 |
19.85 |
421,686 |
5,581 |
13.23 |
955,449 |
21,753 |
22.77 |
Table 3Prevalence of Hyperthyroidism in Patients Undergoing Treatment in 2015
|
Total |
Men |
Women |
Population |
Events |
Prevalencea |
Population |
Events |
Prevalencea |
Population |
Events |
Prevalencea |
Total |
51,834,660 |
143,321 |
2.76 |
25,933,249 |
46,453 |
1.79 |
25,901,411 |
96,868 |
3.74 |
Age group, yr |
|
|
|
|
|
|
|
|
|
≤9 |
4,619,384 |
148 |
0.03 |
2,375,043 |
26 |
0.01 |
2,244,341 |
122 |
0.05 |
10–19 |
5,709,599 |
4,252 |
0.74 |
2,977,410 |
849 |
0.29 |
2,732,189 |
3,403 |
1.25 |
20–29 |
6,881,546 |
11,512 |
1.67 |
3,643,304 |
3,038 |
0.83 |
3,238,242 |
8,474 |
2.62 |
30–39 |
7,824,337 |
23,596 |
3.02 |
4,019,283 |
8,037 |
2.00 |
3,805,054 |
15,559 |
4.09 |
40–49 |
8,871,241 |
31,542 |
3.56 |
4,502,350 |
12,398 |
2.75 |
4,368,891 |
19,144 |
4.38 |
50–59 |
8,332,932 |
34,939 |
4.19 |
4,184,758 |
12,100 |
2.89 |
4,148,174 |
22,839 |
5.51 |
60–69 |
5,064,740 |
21,578 |
4.26 |
2,457,128 |
6,700 |
2.73 |
2,607,612 |
14,878 |
5.71 |
70–79 |
3,153,746 |
12,138 |
3.85 |
1,352,287 |
2,798 |
2.07 |
1,801,459 |
9,340 |
5.18 |
≥80 |
1,377,135 |
3,616 |
2.63 |
421,686 |
507 |
1.20 |
955,449 |
3,109 |
3.25 |